Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tissue inhibitor of metalloproteinase 1 (TIMP-1)
- Target
- TIMP-1
- Molecular classification
- Protease inhibitor, Glycoprotein, Secreted protein, Matrisome-associated protein, Other—TIMP family
01
Overview
Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a 28 kDa secreted glycoprotein belonging to the TIMP family. It is a natural endogenous inhibitor of matrix metalloproteinases (MMPs), enzymes involved in the degradation of the extracellular matrix. By regulating MMPs, TIMP-1 controls tissue remodeling, wound healing, inflammation, and plays roles in pregnancy. TIMP-1 also interacts with cell surface receptors including CD63 and CD82, activating intracellular signaling. Dysregulation of TIMP-1 is implicated in cancer, fibrosis, and other diseases. Its expression is highly inducible by cytokines and hormones. Therapeutic strategies are exploring engineered TIMP-1 variants for greater selectivity against specific MMPs in order to achieve disease-modifying effects.
- Other names
- TIMP metallopeptidase inhibitor 1Erythroid potentiating activity (EPA)Human collagenase inhibitor (HCI)CLGICollagenase inhibitorEPOTIMP
02
Mechanism of action
Inhibition of metalloproteinase activity by direct binding to the catalytic domain; Irreversible inactivation of MMPs via zinc cofactor binding; Modulation of cell signaling via cell-surface receptors.
03
Biological functions
Inhibition of matrix metalloproteinases (MMPs)Regulation of extracellular matrix compositionCell proliferation stimulationAnti-apoptotic functionCell differentiationActivation of cellular signaling via binding to cell-surface receptors (e.g., CD63, CD82, ITGB1)Regulation of erythropoiesis
04
Disease associations
Cancer (prognostic biomarker in various tumors)FibrosisInflammationNeurodegenerative diseasesCardiovascular disease
05
Safety considerations
Therapeutic challenges include nonspecific inhibition of MMPs leading to impaired tissue remodeling, wound healing, or fibrosisPotential off-target effects due to broad expression and systemic functions
06
Interacting drugs
There are no approved drugs directly targeting TIMP-1, but therapeutic protein engineering to enhance TIMP-1's selectivity for MMPs is a developing strategy. Drug candidates include engineered TIMP-1 variants to selectively inhibit disease-driving MMPs such as MMP-3.
07
Biomarkers
Elevated TIMP-1 level correlates with worse prognosis in cancers (such as laryngeal carcinoma, melanoma)Used as a prognostic or disease progression biomarker across cancers and fibrotic diseases
Beyond the preview
Go deeper on Tissue inhibitor of metalloproteinase 1 (TIMP-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tissue inhibitor of metalloproteinase 1 (TIMP-1).